

## PEI Pharmacare Bulletin

Issue (2019 - 10)

November 12, 2019

### NEW PRODUCT(S) ADDED TO THE PEI PHARMACARE FORMULARY (EFFECTIVE DATE: November 25, 2019)

Product (Generic name)	Product (Brand name)	Strength	Dosage Form	DIN	MFR
Emtricitabine/rilpivirine/ tenofovir alafenamide	<b>Odefsey</b>	200 mg/25 mg/25 mg	Tablet	02461463	GIL
Criteria	Open benefit				
Program Eligibility	AIDS/HIV Program				

Product (Generic name)	Product (Brand name)	Strength	Dosage Form	DIN	MFR
Fluticasone/umeclidinium/ vilanterol	<b>Trelegy Ellipta</b>	100 mcg/62.5 mcg/25 mcg	Dry powder for inhalation	02474522	GSK
Criteria	Combination therapy with LABA/LAAC/ICS will be considered for patients with Chronic Obstructive Pulmonary Disease (COPD) who experience inadequate control (persistent symptoms or experiencing 2 or more exacerbations of COPD in the previous year requiring treatment with antibiotics and/or systemic corticosteroids or at least 1 exacerbation requiring hospitalization) while being treated with a LABA/LAAC combination for at least two months.				
Program Eligibility	Family Health Benefit Drug Program, Financial Assistance Program, Seniors Drug Program, Nursing Home Program, Catastrophic Drug Program				

### CRITERIA CHANGE (EFFECTIVE DATE: November 25, 2019)

Product (Generic name)	Product (Brand name)	Strength	Dosage Form	DIN	MFR
Denosumab	<b>Prolia</b>	60 mg/ml	Prefilled Syringe	02343541	AMG
Criteria	<p>The Special Authorization Criteria for Prolia has been updated to the following: For the treatment of osteoporosis in postmenopausal women <b>and in men</b> who meet the following criteria:</p> <ul style="list-style-type: none"> <li>o Have a contraindication to oral bisphosphonates; and</li> <li>o High risk for fracture, or refractory or intolerant to other available osteoporosis therapies.</li> </ul> <p>Clinical Notes:</p> <ul style="list-style-type: none"> <li>• Refractory is defined as a fragility fracture or evidence of a decline in bone mineral density below pre-treatment baseline levels, despite adherence for one year to other available osteoporosis therapies.</li> <li>• High fracture risk is defined as: <ul style="list-style-type: none"> <li>o Moderate 10-year fracture risk (10% to 20%) as defined by the Canadian Association of Radiologists and Osteoporosis Canada (CAROC) tool or the World Health Organization's Fracture Risk Assessment (FRAX) tool with a prior fragility fracture; or</li> <li>o High 10-year fracture risk (<math>\geq 20\%</math>) as defined by the CAROC or FRAX tool.</li> </ul> </li> </ul>				
Program Eligibility	Family Health Benefit Drug Program, Financial Assistance Program, Seniors Drug Program, Nursing Home Program, Catastrophic Drug Program				

## NOTICES

The following products have been removed from PEI Pharmacare Drug Programs, and will no longer be eligible for reimbursement 30 days from this notice (**effective December 12, 2019**):

Adefovir 10 mg tablets

Levofloxacin 750 mg tablets

Vitamin C 500mg tablets

Acyclovir (Zovirax) Cream & Ointment